Cargando…
Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia?
Prepulse inhibition of startle (PPI), a measure of sensorimotor gating used to identify antipsychotics, is reduced in schizophrenia patients and in rodents treated with dopamine agonists or glutamate antagonists. The National institute of Menial Health (NIMH)-funded Measurement And Treatment Researc...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Les Laboratoires Servier
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181759/ https://www.ncbi.nlm.nih.gov/pubmed/16640109 |
_version_ | 1782212805892505600 |
---|---|
author | Geyer, Mark A. |
author_facet | Geyer, Mark A. |
author_sort | Geyer, Mark A. |
collection | PubMed |
description | Prepulse inhibition of startle (PPI), a measure of sensorimotor gating used to identify antipsychotics, is reduced in schizophrenia patients and in rodents treated with dopamine agonists or glutamate antagonists. The National institute of Menial Health (NIMH)-funded Measurement And Treatment Research to improve Cognition in Schizophrenia (MATRICS) program has initiated a new era in the development of procognitive cotreatments in schizophrenia, independently of treating positive symptoms. Although PPI is not a cognitive process per se, such abnormalities in attention may be predictive of or lead to cognitive deficits. Since first-generation antipsychotics block PPI deficits induced by dopamine agonists, this model cannot identify cognitive enhancers for use as cotreatments with antipsychotics, PPI deficits caused by glutamate antagonists, like the exacerbation of symptoms they produce in patients, are insensitive to dopamine antagonists, but reduced by clozapine. Similarly, both PPI and cognitive deficits in schizophrenia patients are insensitive to firstgeneration antipsychotics, but attenuated by clozapine. Hence, treatment-induced reversals of glutamate antagonist effects on PPI may provide animal and human models to identify treatments of cognitive deficits in patients already treated with existing antipsychotics. |
format | Online Article Text |
id | pubmed-3181759 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Les Laboratoires Servier |
record_format | MEDLINE/PubMed |
spelling | pubmed-31817592011-10-27 Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia? Geyer, Mark A. Dialogues Clin Neurosci Basic Research Prepulse inhibition of startle (PPI), a measure of sensorimotor gating used to identify antipsychotics, is reduced in schizophrenia patients and in rodents treated with dopamine agonists or glutamate antagonists. The National institute of Menial Health (NIMH)-funded Measurement And Treatment Research to improve Cognition in Schizophrenia (MATRICS) program has initiated a new era in the development of procognitive cotreatments in schizophrenia, independently of treating positive symptoms. Although PPI is not a cognitive process per se, such abnormalities in attention may be predictive of or lead to cognitive deficits. Since first-generation antipsychotics block PPI deficits induced by dopamine agonists, this model cannot identify cognitive enhancers for use as cotreatments with antipsychotics, PPI deficits caused by glutamate antagonists, like the exacerbation of symptoms they produce in patients, are insensitive to dopamine antagonists, but reduced by clozapine. Similarly, both PPI and cognitive deficits in schizophrenia patients are insensitive to firstgeneration antipsychotics, but attenuated by clozapine. Hence, treatment-induced reversals of glutamate antagonist effects on PPI may provide animal and human models to identify treatments of cognitive deficits in patients already treated with existing antipsychotics. Les Laboratoires Servier 2006-03 /pmc/articles/PMC3181759/ /pubmed/16640109 Text en Copyright: © 2006 LLS http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Basic Research Geyer, Mark A. Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia? |
title | Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia? |
title_full | Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia? |
title_fullStr | Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia? |
title_full_unstemmed | Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia? |
title_short | Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia? |
title_sort | are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia? |
topic | Basic Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181759/ https://www.ncbi.nlm.nih.gov/pubmed/16640109 |
work_keys_str_mv | AT geyermarka arecrossspeciesmeasuresofsensorimotorgatingusefulforthediscoveryofprocognitivecotreatmentsforschizophrenia |